Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

XTL Biopharmaceuticals Ltd ADR

Company price
1.54 USD -0.08 ( 4.94%)
Last update at 2026-11-18T21:00:00Z
VOLUME
8251
Market Cap
14.22M

Momentum Score

…

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.54
Low
1.68
High
52 Week Price Range
0.75
Low
4.99
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

XTL Biopharmaceuticals Ltd ADR is a small, publicly listed biopharmaceutical company; publicly available information about its pipeline and commercial products is limited. Its long-term growth may depend on progression of therapeutic candidates through clinical development, successful licensing or partnerships, and regulatory approvals that could support commercialization, and investors may find exposure to potential upside from clinical-stage therapeutics attractive if development milestones are achieved.
The main risks include early-stage development and clinical and regulatory failure, limited public disclosure and liquidity, and the need for additional financing that could dilute shareholders.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.62
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-13.07%
Net Debt
-1.40M
ROCE
-39.64%
Diluted EPS TTM
-0.03

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -1.35M 0.43M -0.78M -1.35M 2.99M
Net income -2.31M 1.90M -0.62M -1.28M 2.99M
Selling general administrative 0.85M 1.00M 0.91M 0.81M 0.76M
Gross profit -0.46M 1.47M 0.03M 0.07M 0.05M
Reconciled depreciation 0.00M 0.00M 0.00M 0.00M -
Ebit -0.88M -1.03M -0.95M -0.84M -8.35M
Ebitda -0.39M -2.50M -1.08M -0.27M -4.49M
Depreciation and amortization 0.49M -1.47M -0.14M 0.57M 3.86M
Operating income -0.88M -1.03M -0.95M -0.84M -0.79M
Other operating expenses 0.88M 1.03M 0.95M 0.84M 0.79M
Interest expense 0.47M 1.47M 0.03M 0.03M 0.08M
Interest income 0.04M 0.01M 0.03M 0.09M 0.09M
Net interest income 0.03M 0.00M 0.02M 0.06M 0.08M
Income tax expense 0.96M -1.47M -0.17M -0.07M -7.64M
Total revenue -0.46M 1.47M 0.03M 0.07M 0.05M
Total operating expenses 0.88M 1.03M 0.95M 0.84M 0.79M
Cost of revenue - - - - 0.00M
Total other income expense net -0.47M 1.47M 0.17M -0.51M 3.70M
Net income from continuing ops -1.35M 0.43M -0.78M -1.35M 2.99M
Net income applicable to common shares -1.35M 0.43M -2.95M -1.35M 2.99M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 2.43M 4.19M 6.62M 6.50M 7.21M
Intangible assets 0.38M 0.38M 0.38M 0.38M 0.38M
Other current assets 0.01M 0.01M 0.02M 0.01M 0.10M
Total liab 0.21M 0.19M 1.28M 0.25M 0.23M
Total stockholder equity 2.22M 4.00M 5.33M 6.25M 6.98M
Other current liab 0.20M 0.18M 0.23M 0.25M 0.23M
Common stock 14.12M 14.12M 14.12M 13.18M 13.18M
Capital stock 14.12M 14.12M 14.12M 13.18M 13.18M
Retained earnings -158.25M -156.47M -155.13M -154.66M -153.93M
Other liab - - 1.05M 2.64M 0.47M
Cash 1.40M 2.09M 2.97M 3.63M 4.46M
Total current liabilities 0.21M 0.19M 0.23M 0.25M 0.23M
Net debt -1.40M -2.09M -2.97M -3.63M -4.46M
Other stockholder equity 0.15M 146.33M 146.33M 147.71M 147.71M
Property plant equipment - - 0.00M 0.00M 0.00M
Total current assets 2.05M 3.81M 6.24M 6.12M 6.83M
Net tangible assets - 3.62M 4.95M 3.23M 6.60M
Short term investments 0.60M 1.63M 3.16M 2.41M 2.27M
Net receivables 0.03M - - - -
Accounts payable 0.00M 0.00M 0.00M 0.00M 0.00M
Accumulated other comprehensive income 0.02M 0.02M 0.02M 0.02M 0.02M
Common stock total equity - - - 13.18M 13.18M
Non currrent assets other 0.60M - - - 0.00M
Non current assets total 0.38M 0.38M 0.38M 0.38M 0.38M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 0.04M 0.04M 0.01M 0.03M 2.11M
Change to liabilities - 0.00M -0.02M 0.02M -0.02M
Total cashflows from investing activities - 0.04M 0.01M 0.03M 2.11M
Total cash from financing activities 0.00M 0.00M 0.39M 0.39M 0.39M
Change to operating activities - - -0.03M 0.02M -0.03M
Net income -1.78M -1.35M 0.43M -0.78M -1.35M
Change in cash -0.69M -0.88M -0.66M -0.82M 1.20M
Begin period cash flow 2.09M 2.97M 3.63M 4.46M 3.25M
End period cash flow 1.40M 2.09M 2.97M 3.63M 4.46M
Total cash from operating activities -0.71M -0.90M -1.05M -0.85M -0.91M
Issuance of capital stock - - - - 0.00M
Depreciation 0.00M 0.00M 0.00M 0.00M 0.00M
Other cashflows from investing activities - 0.04M 0.01M 0.03M 0.09M
Other cashflows from financing activities 0.04M 0.04M 0.39M 0.03M 2.11M
Change to netincome - 0.45M -1.43M -0.11M 0.49M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.06M -0.02M -0.05M 0.04M -0.05M
Stock based compensation 0.00M 0.01M 0.04M 0.05M 0.01M
Other non cash items -0.04M 0.45M -0.01M -0.03M 0.48M
Free cash flow -0.71M -0.90M -1.05M -0.85M -0.91M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
XTLB
XTL Biopharmaceuticals Ltd ADR
-0.08
4.94%
1.54 - - - 5.67 -6.58
NVO
Novo Nordisk A/S
-1.25
3.07%
39.45 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc
-
-%
536.45 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc
-9.75
1.02%
948.01 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 36.06

Profile*

XTL Biopharmaceuticals Ltd ADR

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

5 Badner Street, Ramat Gan, Israel, 5218102

972 3 611 6600

Name Title Year Born
Mr. Shlomo Spokone Shalev CEO & Director 1962
Mr. Itay Weinstein Chief Financial Officer 1971
Mr. Ronen Kantor Company Sec. NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…